Overexpression of Her2/neu has been found to be associated with resistance to chemotherapy and poor survival in multiple human malignancies, particularly in breast cancer, where Her2/neu has been most extensively studied (Wright et al, 1989; Lofts and Gullick, 1992). Here, ERBB2 is linked to breast carcinoma.